Related Experiment Videos
Erythromycin. New indications and toxicities
Abstract:
Although erythromycin was introduced into clinical medicine more than 28 years ago, the indications for its use continue to expand. This antibiotic has emerged as appropriate therapy for Legionnaires' disease, chronic bacterial prostatitis caused by Escherichia coli, Klebsiella pneumoniae, and Proteus species, enteritis and colitis produced by Campylobacter fetus, and soft tissue and pleuropulmonary anaerobic infections in which Bacteroides fragilis plays no role. In combination with an aminoglycoside, erythromycin has proven to be effective for perioperative antibiotic prophylaxis in patients undergoing elective colon surgery. Additional therapeutic indications continue to be explored. The renewed interest in erythromycin has resulted in a closer examination of its potential for toxicity. New untoward events attributed to erythromycin administration have been described. This antibiotic has produced both reversible hearing loss and pseudomembranous colitis. Erythromycin also possesses the ability to inhibit the degradation of theophylline.
Insights
Erythromycin, an antibiotic, has expanding clinical uses for various infections and prophylaxis. However, potential toxicities like hearing loss and colitis require careful consideration.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Erythromycin has been clinically available for over 28 years.
- Its therapeutic applications continue to broaden beyond initial uses.
Purpose of the Study:
- To review the expanding indications for erythromycin therapy.
- To examine the potential toxicities associated with erythromycin use.
Main Methods:
- Literature review of clinical applications and adverse events.
- Analysis of case reports and clinical studies on erythromycin.
Main Results:
- Erythromycin is effective for Legionnaires' disease, specific prostatitis, Campylobacter infections, and certain anaerobic infections.
- It shows efficacy in perioperative prophylaxis for colon surgery when combined with an aminoglycoside.
- Adverse events include reversible hearing loss and pseudomembranous colitis.
Conclusions:
- Erythromycin remains a valuable antibiotic with evolving indications.
- Clinicians must be aware of and monitor for potential adverse effects, including ototoxicity and C. difficile-associated colitis.
- Erythromycin's interaction with theophylline metabolism is also noted.